MedTrace Logo

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

NCT07466927 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-12

No results posted yet for this study

Summary

This is a prospective, open-label, phase II platform trial. The purpose of this study is to test the safety and effectiveness of multi-mode thermal therapy combined with immunotherapy in patients with HER2-negative breast cancer with liver metastases who had previously received systemic therapy

Conditions

Interventions

DRUG

SHR-A1811

A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.

DRUG

SKB264

A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.

DRUG

Pembrolizumab

PD-1 antibody, via intravenous (into the vein) infusion per protocol.

DRUG

SHR-1316

PD-L1 antibody, via intravenous (into the vein) infusion per protocol.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-15
Primary Completion
2028-01-15
Completion
2029-01-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07466927 on ClinicalTrials.gov